Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co has the Financial Strength Rank of 8. It shows strong financial strength and is unlikely to fall into distressed situations.
Good Sign:
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd shows strong financial strength.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is rated on a scale of 1 to 10 and is based on these factors:
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.
4. Other debt related ratios.
A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co did not have earnings to cover the interest expense.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's debt to revenue ratio for the quarter that ended in Dec. 2025 was 0.03.
As of today, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Altman Z-Score is 15.90.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (FRA:FDY) Financial Strength Explanation
The rank is rated on a scale of 1 to 10. A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co has the Financial Strength Rank of 8. It shows strong financial strength and is unlikely to fall into distressed situations.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Financial Strength Related Terms
FRA:FDY vs ZTS: Financial Strength Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Financial Strength vs Drug Manufacturers Industry
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co has a Z-score of 15.90, indicating it is in Safe Zones. This implies the Z-Score is strong.
Good Sign:
Altman Z-score of 15.9 is strong.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (FRA:FDY) has a Financial Strength of 8 as of Dec. 2025. The financial strength rank measures the strength of a company's balance sheet based on revenue and debt. View historical data on Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co and its competitors. This is 20% below median its historical median of 10.00. Over the past decade, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Financial Strength has ranged from 3.00 to 10.00.
Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Financial Strength too high?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's current Financial Strength of 8 is 20% below median its 10-year median of 10.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 10.00. Overall, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co has a GF Score™ of 71/100, reflecting its overall financial health beyond just this single metric.
How does Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Financial Strength compare to ZTS?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Financial Strength of 8 can be compared against companies in the Drug Manufacturers industry. Historically, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's own Financial Strength has ranged from 3.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Financial Strength for a Drug Manufacturers company?
A good Financial Strength depends on the Drug Manufacturers industry context. However, Financial Strength should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Financial Strength mean?
A high Financial Strength can signal that a stock is expensive relative to its fundamentals. The financial strength rank measures the strength of a company's balance sheet based on revenue and debt. View historical data on Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co and its competitors. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's current Financial Strength is 8, which is 20% below median its own 10-year median of 10.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co stock overvalued right now?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (FRA:FDY) has a current Financial Strength of 8. The stock's GF Value™ is €0.23, compared to a current price of €0.27 — trading 17.4% above its estimated fair value. The current Financial Strength is 8, which is 20% below median its 10-year median of 10.00. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's overall GF Score™ is 71/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Financial Strength calculated?
Financial Strength is calculated from a company's financial statements. For Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (FRA:FDY), the current Financial Strength is 8 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (FRA:FDY) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co stock appears to be overvalued.
The current stock price of €0.27 is trading 17.4% above its estimated GF Value™ of €0.23.
Key valuation signals for FRA:FDY:
Financial Strength: 8 (20% below median its 10-year median of 10.00)
GF Value™: €0.23 vs. price of €0.27 (17.4% above fair value)
No single metric tells the full story. See the FRA:FDY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is engaged in the research, development, manufacturing, and sale of biopharmaceutical products. Its product portfolio includes ALA (Aminolevulinic acid Hydrochloride); FuMeiDa and Libord. The company has launched it's four types of photodynamic drugs in China market, namely hematoporphyrin, aminolevulinic acid hydrochloride, Verteporfin and Hemoporfin. Geographically, it derives revenue from Mainland China.
71GF Score
Get the complete analysis for FRA:FDY
Financial Strength is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:FDY has been successfully added to your 
